Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

MLA

Weisberg, Ellen, et al. “Potentiation of Antileukemic Therapies by the Dual PI3K/PDK-1 Inhibitor, BAG956: Effects on BCR-ABL- and Mutant FLT3-Expressing Cells.” Blood, vol. 111, no. 7, Apr. 2008, pp. 3723–34. EBSCOhost, https://doi.org/10.1182/blood-2007-09-114454.

APA

Weisberg, E., Banerji, L., Wright, R. D., Barrett, R., Ray, A., Moreno, D., Catley, L., Jiang, J., Hall-Meyers, E., Sauveur-Michel, M., Stone, R., Galinsky, I., Fox, E., Kung, A. L., & Griffin, J. D. (2008). Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood, 111(7), 3723–3734. https://doi.org/10.1182/blood-2007-09-114454

Chicago

Weisberg, Ellen, Lolita Banerji, Renee D Wright, Rosemary Barrett, Arghya Ray, Daisy Moreno, Laurence Catley, et al. 2008. “Potentiation of Antileukemic Therapies by the Dual PI3K/PDK-1 Inhibitor, BAG956: Effects on BCR-ABL- and Mutant FLT3-Expressing Cells.” Blood 111 (7): 3723–34. doi:10.1182/blood-2007-09-114454.